Platelet-rich plasma for the knee: clinical indications

Platelet-rich plasma for the knee: what it is and where it comes from

Platelet-rich plasma for the knee is one of the regenerative treatments that generates the most questions ahead of a consultation. The reason is understandable: information is scattered, expectations vary widely, and there is little clarity about what it does and what it does not. Our clinical team at Longevia explains it using the same language we use in the assessment.

Platelet-rich plasma, or PRP, is obtained from the patient's own blood. In general terms, a blood sample is processed to concentrate platelets into a small volume of plasma. That concentrate is then applied to the target area. It does not contain stem cells. It is an autologous blood derivative: it comes from you and returns to you, with a higher concentration of growth factors than what circulates in ordinary blood.

Distinguishing PRP from stem cell therapies matters because the two are not equivalent or interchangeable. If you are researching both options, the article on how to evaluate a stem cell therapy clinic in Mexico can orient you on selection criteria for that type of treatment.

Accepted indications: when platelet-rich plasma for the knee has clinical support

PRP in the knee has its most studied field of application in two contexts: mild to moderate joint degeneration and certain tendon injuries. In early-stage or mid-grade osteoarthritis, available evidence suggests it may contribute to reducing inflammation and improving function. The operative phrase is "may contribute": the effect varies and depends on individual factors assessed before any decision is made.

For tendon injuries around the knee, PRP also appears in the clinical literature as an option worth considering. The criterion is not the diagnosis alone, but the combination of diagnosis, stage, injury history, and response to prior treatments.

What current evidence does not support with the same consistency is its use in advanced osteoarthritis, where cartilage loss is extensive. In those cases, the growth factors in PRP have less tissue substrate to act on. That does not mean the option is dismissed without review; it means the indication becomes considerably narrower and the decision requires closer clinical scrutiny.

PRP for the knee is not a second-line treatment for patients who want to avoid surgery. It is an indication with its own criteria, evaluated case by case.

What remains under investigation: knee PRP and what is not yet conclusive

Several aspects of PRP for the knee remain active areas of study. The optimal number of sessions, the interval between them, the most appropriate platelet concentration by lesion type, and the patient profiles that respond best: all of these parameters are still being refined. The fact that they are under investigation does not mean the treatment is experimental; it means protocol personalization continues to develop.

The combination of PRP with other regenerative interventions is also being studied. Results from those combinations do not yet have enough follow-up to be considered standard. When a patient presents with a complex case, the clinical assessment must be honest about what is established and what is not.

What is clear is what PRP does not do: it does not regenerate destroyed cartilage, it does not correct mechanical alignment, and it does not replace surgical intervention when that is indicated. Those limits are not a shortcoming of the treatment; they are part of understanding it properly.

How candidacy for platelet-rich plasma in the knee is determined

The decision does not start with the treatment: it starts with you. A detailed clinical history, up-to-date imaging, symptoms and their progression over time, prior treatments and their responses: all of this forms the picture on which the indication is evaluated. Without that information, any decision is premature.

Imaging studies play a specific role. An X-ray allows assessment of joint space and osteoarthritis grade. An MRI provides information on cartilage condition, menisci, and soft tissue. PRP is not prescribed on the basis of symptoms alone or imaging alone: both elements are integrated.

The number of sessions is not fixed. In general clinical practice, a protocol may involve a single session or a series of them, depending on the diagnosis, response, and therapeutic objective. That is determined during the assessment and communicated in a written plan. Follow-up, which continues even after the patient returns home, allows the protocol to be adjusted if needed.

flowchart TD
    A["Clinical history and symptoms"] --> B["Imaging studies"]
    B --> C{"Degree of degeneration"}
    C -->|"Mild to moderate"| D["Candidacy evaluation for PRP"]
    C -->|"Advanced"| E["Other clinical options"]
    D --> F["Individual written protocol"]
    F --> G["Session series according to indication"]
    G --> H["Follow-up and protocol adjustment"]

Platelet-rich plasma for the knee: what to expect from the procedure and warning signs

In general terms, a PRP injection in the knee is an outpatient procedure. Post-procedure discomfort varies: there may be a sensation of tightness or local soreness in the hours that follow. That is part of the initial inflammatory response the process itself triggers.

What is neither expected nor acceptable is intense pain, skin discoloration around the joint, fever, or any new neurological symptom. If after a knee injection you experience severe and sustained pain, the skin turns white or purple, you have difficulty breathing, or any symptom falls outside the usual pattern, that requires emergency care immediately, not a message to the clinic.

Candidacy for PRP is not determined by the desire to avoid surgery or by a history of unsuccessful treatments. It is determined by what clinical assessment and imaging show together.

Frequently asked questions about platelet-rich plasma for the knee

Frequently asked questions

Is platelet-rich plasma for the knee the same as stem cells?

No. PRP is obtained from the patient's own blood by concentrating platelets and growth factors. It does not contain stem cells. They are two distinct tools with distinct indications, and the choice between them depends on clinical assessment and imaging.

For what type of knee osteoarthritis is PRP appropriate?

The most consistent clinical support corresponds to mild to moderate joint degeneration. In advanced osteoarthritis with extensive cartilage loss, the indication becomes very narrow because there is less tissue to act on. The exact grade is determined with up-to-date imaging.

How many PRP sessions does the knee need?

The number of sessions is not standardized. It depends on the diagnosis, the degree of injury, and the response to treatment. It may be a single session or a series of them. The protocol is established during the assessment and delivered in writing with the corresponding follow-up plan.

How long does the effect of platelet-rich plasma in the knee last?

The duration of the effect varies and depends on the patient's profile, the degree of degeneration, and factors such as physical activity and body weight. No one can promise you an exact duration. Periodic follow-up makes it possible to assess the response and determine whether another cycle is warranted.

How do I know if I am a candidate for platelet-rich plasma for the knee?

Candidacy is established with a complete clinical history and up-to-date imaging studies. There is no way to determine it without that information. At Longevia Medical, the assessment can be conducted in person at Puerto Cancún or remotely, and the plan is delivered in writing.

Platelet-rich plasma for the knee: where it fits within a clinical plan

PRP is neither the starting point of a joint health plan nor its endpoint. It is one tool within a broader context that may include load management, weight control, physiotherapy, and in some cases, other interventions. How those elements are combined depends on each individual case.

At Longevia Medical, care begins with an assessment, in person at Puerto Cancún or remotely. The plan is individual and delivered in writing. Medical supervision accompanies the process, and follow-up continues after the patient returns home.

If you want to broaden your perspective on regenerative options for the knee and the criteria that distinguish a rigorous protocol, the article on how to evaluate a stem cell therapy clinic in Mexico offers a useful framework for asking informed questions.

For those who wish to review reference information on joint health and blood-derived therapies, Mayo Clinic and MedlinePlus publish general resources in accessible language for patients.